Analysis of the Relationship between Inflammatory Activity and Fecal Calprotectin Levels and Fecal Occult Blood as Biomarkers for Gastritis Sufferers

Main Article Content

Diah Lestari
Nurhikmah
Lyana Setiawan

Abstract

Gastritis is a disease in the form of inflammation of the stomach. Inflammatory activity in gastritis sufferers can be detected through biomarker examinations such as fecal calprotectin and fecal occult blood tests (FOB). This study was to analyze the relationship between inflammatory activity and fecal calprotectin levels and occult blood as a biomarker in chronic gastritis sufferers. The research method uses a cross-sectional design, Chi-Square statistical test data analysis, with a confidence level of 95% (α 0.05). The research used secondary data with a sample size of 64 people suffering from chronic gastritis who experienced inflammation that developed gradually over a long period of time. Research variables were obtained from Local Information System (LIS) Laboratory data for inflammatory activity of non-active chronic gastritis and histologically active chronic gastritis, fecal calprotectin and occult blood from the measurement results of the fecal calprotectin reagent test kit insert and FOB oncoprobe. The results of the study showed that 30.4% of positive occult blood and 54.3% fecal calprotectin levels increased significantly in non-active chronic gastritis inflammatory activity. The results of the analysis showed that there was no significant relationship between inflammatory activity and fecal calprotectin levels with a p-value of 0.413 (p>0.05) and there was no relationship between inflammatory activity and occult blood (FOB) p-value 1.000 (p>0.05 ) in chronic gastritis sufferers. The conclusion is that there is no significant relationship between inflammatory activity and fecal calprotectin levels and occult blood as a biomarker in chronic gastritis sufferers.

Article Details

How to Cite
Diah Lestari, Nurhikmah, & Lyana Setiawan. (2024). Analysis of the Relationship between Inflammatory Activity and Fecal Calprotectin Levels and Fecal Occult Blood as Biomarkers for Gastritis Sufferers. International Journal of Pharmaceutical and Bio Medical Science, 4(9), 730–735. https://doi.org/10.47191/ijpbms/v4-i9-02
Section
Articles

References

I. Suwindri et al, “Faktor Penyebab Kejadian Gastritis Di Indonesia : Literature Review Mahasiswa IKesT Muhammadiyah Palembang , Sumatera Selatan , Indonesia IKesT Muhammadiyah Palembang , Sumatera Selatan , Indonesia,” vol. 1, no. November, pp. 209–223, 2021.

II. P. Oktariana, L. F. Krishna, A. K. K. Gastrits, and B. K. P. B. Kesehatan, “No Title,” vol. 3, no. 2. doi: 10.36971/keperawatan.v3i2.54, 2019.

III. JAngkow, F. Robot, and F. Onibala, “Faktor-Faktor Yang Berhubungan Dengan Kejadian Gastritis Di Wilayah Kerja Puskesmas Bahu Kota Manado”,” J. Keperawatan, vol. 2, no. 2, doi: 10.35790/jkp.v2i2.5277, 2014.

IV. Riskesdas, “Laporan Riskesdas 2018 Kementrian Kesehatan Republik Indonesia [Internet,” Lap. Nas. Riskesdas. Publ..Colovic et al., 2013)

V. W. G. W. Pathirana, S. P. Chubb, M. J. Gillett, and S. D. Vasikaran, “Faecal Calprotectin,” Clin Biochem Rev, vol. 39, no. 3, pp. 77–90, 2018. .

VI. M. Manz, E. Burri, C. Rothen, N. Tchanguizi, C. Niederberger, and L. Rossi, “Nilai fecal calprotectin dalam evaluasi pasien dengan ketidaknyamanan perut: sebuah studi observasional,” BMC Gastroenterol, vol. 12, no. 5, 2012..

VII. E. Burri and C. Beglinger, “Penggunaan fecal calprotectin sebagai biomarker pada penyakit gastrointestinal,” Ahli Rev Gastroenterol Hepatol, vol. 8, pp. 197–210,2014.

VIII. R. E. Davila, E. Rajan, and T. H. Baron, “Standards of Practice Committee, American Society for Gastrointestinal Endoscopy ASGE guideline: colorectal cancer screening and surveillance,” Gastrointest Endosc, vol. 63, pp. 546–57.

IX. K. Sugano, J. Tack, and E. J. Kuipers, Laporan Konsensus Global Kyoto Mengenai Gastritis Helicobacter Pylori, 9th ed., vol. 64. Usus, 2015.

X. F. Weise, M. Vieth, and D. Reinhold, “Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research,” United Eur. Gastroenterol. J., vol. 8, no. 2, pp. 175–184, doi: 10.1177/2050640619891580, 2020.

XI. Y. Fu, L. Wang, and C. Xie, “Perbandingan biomarker non-invasif BAFF feses, calprotectin dan FOBT dalam membedakan IBS dari IBD dan evaluasi peradangan usus,” Rep Sains, vol. 7, p. 2017 2669, doi: 10.1038/s41598-017-02835-5, 2017.

XII. Y. Fu, L. Wang, and C. Xie, “Perbandingan biomarker non-invasif BAFF feses, calprotectin dan FOBT dalam membedakan IBS dari IBD dan evaluasi peradangan usus,” Rep Sains, vol. 7, p. 2017 2669, doi: 10.1038/s41598-017-02835-5, 2017.

XIII. G. Pennelli, F. Grillo, and F. Galuppini, “Gastritis: update on etiological features and histological practical approach,” Pathologica, vol. 112, no. 3, pp. 153–165, doi: 10.32074/1591-951X-163, 2020.

XIV. P. Sipponen and H. Maaroos, “Chronic gastritis,” no. February, pp. 657–667, 2015, doi: 10.3109/00365521.2015.1019918.

XV. P. O. Katz and L. B. Gerson, “Gastritis and Gastropathy,” in Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, Elsevier.2016.

XVI. L. Laine, K. Takeuchi, and A. Tarnawski, “Gastric mucosal defense and cytoprotection: bench to bedside,” Gastroenterology, vol. 135, no. 1, pp. 41–60, doi: 10.1053/j.gastro.2008.05.030.

XVII. Y.-C. Lee, H.-M. Chiu, and T.-H. Chiang, “Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions,” BMJ Open, vol. 3:e003989, doi: 10.1136/bmjopen-2013-.

XVIII F. D. Angelo and J. Louis, “Calprotectin in Daily Practice : Where Do We Stand in 2017 ?,” pp. 293–301, 2017, doi: 10.1159/000476062.

XIX. L. Y. Mak, T. S. M. Tong, and K. S. Cheung, “Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease,” Clin Transl Gastroenterol, vol. 11, no. 3, doi: 10.14309/ctg.0000000000000138.2020

XX. F. D. Saya, G. Ç. Ii, H. Abbasguliyev, A. K. U. Aku, A. Gazi, and K. Iv, “Kadar calprotectin tinja digunakan sebagai metode non-invasif untuk skrining maag kronis pada pasien anak . Sebuah penelitian deskriptif,” vol. 139, no. 6, pp. 564–569, 2021.

XXI Ö. Y. Aksoy, O. Canan, F. Ö. Hoşnut, E. Akçay, and F. Özçay, “Fecal calprotectin levels in Helicobacter pylori gastritis in children,” Turk J Pediatr, vol. 62, no. 6, pp. 986–993, doi: 10.24953/turkjped.2020.06.010.